<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289702</url>
  </required_header>
  <id_info>
    <org_study_id>MT03-KR16MST907</org_study_id>
    <nct_id>NCT03289702</nct_id>
  </id_info>
  <brief_title>CORETOX® in Treatment of Post Stroke Upper Limb Spasticity</brief_title>
  <official_title>A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment
      of Post stroke upper limb spasticity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAS(Modified Ashworth Scale)of wrist flexor</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change from baseline at week 4 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MAS(modified Ashworth Score)of elbow and finger flexor</measure>
    <time_frame>4 weeks after injection</time_frame>
    <description>Change from baseline at week 4 for elbow flexor and finger flexor muscle tone as measured on MAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAS(modified Ashworth Score)of wrist, elbow and finger flexor</measure>
    <time_frame>8, 12 weeks after injection</time_frame>
    <description>Change from baseline at week 8, 12 for wrist flexor, elbow flexor and finger flexor muscle tone as measured on MAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of treatment responder at week 4, 8, 12 after injection</measure>
    <time_frame>4, 8, 12 weeks after injection</time_frame>
    <description>A treatment response is defined as 1-point improvement on the MAS of injection site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Muscle Spasticity</condition>
  <arm_group>
    <arm_group_label>CORETOX®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORETOX®</intervention_name>
    <description>upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.</description>
    <arm_group_label>CORETOX®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX®</intervention_name>
    <description>upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.</description>
    <arm_group_label>BOTOX®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥ 19 years

          -  ≥ 6 weeks since the last stroke

          -  ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 points at least one of
             elbow flexor and finger flexor as measured on MAS(0 to 4)

          -  Informed consent has been obtained

        Exclusion Criteria:

          -  Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or
             amyotrophic lateral sclerosis

          -  History(within 4 months of screening visit) or planned(during study period) treatment
             with phenol or alcohol injection or surgery in the target limb

          -  History(within 4 months of screening visit) or planned(during study period) treatment
             with tendon lengthening in the target limb

          -  Fixed joint/muscle contracture

          -  Severe atrophy

          -  Concurrent treatment with an intrathecal baclofen

          -  Patients who have bleeding tendency or taking anti-coagulant

          -  Dysphagia and Breathing Difficulties

          -  History(within 4 months of screening visit) Planned(during study period) treatment
             with Botulinum Toxin

          -  Known allergy or sensitivity to study medication or its components

          -  Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has
             taken these medication stable from one month before screening and no treatment changes
             are not planned during the study, participation is allowed.

          -  Current Physical, occupational, Splinting therapy If these therapy regimens will be
             permitted if they has been stable in the one month before screening;no treatment and
             no changes are planned during the study.

          -  Patient who are participating in other clinical trials at the screening

          -  Females who are pregnant, breatfeeding,or planning a pregnancy during the study
             period, or female of childbearing potential, not using a reliable means of
             centraception.

          -  Patients who are not eligible for this study at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rang Lee</last_name>
    <phone>82-2-6901-5869</phone>
    <email>rang531@medytox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minho Chun</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

